CoChat

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer

Open access
Lamberti, G., Spurr, L.F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L.M., Meyerson, M.L., Cherniack, A.D., Awad, M.M. · 2020 · Annals of Oncology
Cited by 98

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

INTRODUCTION Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in non-small cell lung cancer (NSCLC), but factors associated with PD-L1 expression are not well understood. METHODS Consecutive nonsquamous NSCLCs with successful PD-L1 assessment and targeted next-generation sequencing (NGS) were included in this retrospective study. Clinicopathological characteristics, gene mutations, and copy number changes in gene and chromosomal arms were compared among three PD-L1 expression groups: negative (TPS <1%), low (TPS 1-49%), and high (TPS ≥50%). A Q-value <0.25 was considered significant after multiple comparisons correction. RESULTS A total of 909 nonsquamous NSCLCs were included. High PD-L1 expression compared to low and negative PD-L1 expression was associated with increased tobacco exposure (median pack-years: 25 vs. 20 vs. 20, respectively; P=0.01), advanced stage at diagnosis (76% vs. 67% vs. 61% with advanced stage of disease, respectively; P<0.001), and higher TMB (median 12.2 vs. 10.6 vs. 10.6 mutations/megabase, respectively; P<0.001). Negative PD-L1 expression when compared with high PD-L1 expression was associated with: mutations in STK11 (19% vs. 5%; Q<0.001), EGFR (22% vs. 11%; Q<0.001), CTNNB1 (4.3% vs. 0.4%; Q=0.04), APC (5% vs. 1%; Q=0.17), and SMARCA4 (9% vs. 4%; Q=0.20); copy number loss of CD274 (PD-L1, 28% vs. 6%; Q<0.001), PDCD1LG2 (PD-L2, 28% vs. 6%; Q<0.001), and JAK2 genes (27% vs. 7%; Q<0.001), loss of chromosomal arm 9p (23% vs. 10%; Q=0.04), and gain of 1q (46% vs. 21%; Q<0.001). High PD-L1 expression compared to negative PD-L1 expression was associated with copy number gain of CD274 (11% vs. 3%; Q=0.01) and PDCD1LG2 (11% vs. 3%; Q=0.01). NSCLCs with CD274 loss, compared to those without loss, had a lower response rate (23% vs. 9%; P=0.006) and shorter progression-free survival (3.3 vs. 2.0 months; P=0.002) on immunotherapy. CONCLUSIONS PD-L1 expression is associated with specific genomic alterations and clinicopathologic characteristics in nonsquamous NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2020.02.017

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 98

Metadata

Authors
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., & Awad, M. M.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2020-06
Volume
31
Issue
6
Pages
807-814
ISSN
0923-7534 (ISSN-L)
OpenAlex
W3012365695
Cited by
98
References
8
FWCI
5.45
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. https://app.cochat.ai/papers/10.1016/j.annonc.2020.02.017
The paper
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., & Awad, M. M. (2020). Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Annals of Oncology. https://doi.org/10.1016/j.annonc.2020.02.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.